This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Comment: US FTC's Amgen-Horizon challenge could chill healthcare M&A, but has high hurdle with risky conglomerate theory

By Ilana Kowarski and Flavia Fortes ( May 26, 2023, 21:20 GMT | Comment) -- A US Federal Trade Commission lawsuit to block Amgen’s proposed acquisition of Horizon Therapeutics has potentially serious ramifications for dealmaking in the healthcare sector, but the agency took a bold risk with a hard-to-prove theory of harm that still needs to be validated by a judge.A US Federal Trade Commission lawsuit to block Amgen’s proposed acquisition of Horizon Therapeutics has potentially serious ramifications for dealmaking in the healthcare sector, but the agency took a bold risk with a hard-to-prove theory of harm that still needs to be validated by a judge....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login